M2 PHARMA-April 29, 2014-Cancer Advances gets US patent allowance for monoclonal antibodies to progastrin
29 April 2014 - Cancer Advances Inc, a fully-owned biotech portfolio company of US Cato BioVentures, said Tuesday it had received allowance for a US divisional patent covering monoclonal antibodies to progastrin, the unprocessed precursor to the gastrin hormone.
The allowed claims will grant the company exclusive rights to utilise high specificity monoclonal antibodies against progastrin to treat ulcers and cancers.
Insulin-like growth factors are more effective than progastrin
in reversing proapoptotic effects of curcumin: critical role of p38MAPK.
In gastrinoma cells, progastrin is processed less efficiently than in normal gastrin cells (8,25).
A few gastrinomas, however, may process progastrin so poorly that the concentrations of bioactive amidated gastrins in plasma periodically fluctuate into the reference interval [104 pg/mL (<50 pmol/L)] while the concentrations of precursors are increased (27, 38).
Progastrin processing during antral G-cell hypersecretion in humans.
PIA was first applied to progastrin and procholecystokinin (7-9), and recent reports illustrate its diagnostic advantages (5, 6,10-14).
These results are in accordance with reports that PIA analyses have increased the diagnostic accuracy for progastrin (6,10), probrain natriuretic peptide, and rat epidermal growth factor (11, 24).
As a result of the elaborate cellular maturation process of progastrin, the antral G cells release a mixture of different acidstimulatory gastrins and other precursor fragments to the circulation (2).
Progastrin in pancreas and the Zollinger-Ellison syndrome.
As previously and originally described for progastrin
measurement (6), enzymatic treatment of plasma with trypsin was performed before measurement to cleave all proBNP peptides to the 1-21 fragment.